کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5532126 | 1549616 | 2017 | 9 صفحه PDF | دانلود رایگان |
BackgroundMany factors contribute for viral clearance and response to antiviral therapy. Genetic polymorphisms of cytokines, chemokines, and their receptors can alter the immune response against Hepatitis C virus (HCV).Aim of the studyThe aim of the current study is to assess single nucleotide polymorphism (SNP) in the promoter region of IL-10, TNF-α, IFN-γ and TGF-β as predictors of response to combined Pegylated interferon α/ribavirin (PEG-IFN/RBV) therapy in chronic HCV infected Egyptian patients.Patients and methodsThe study was conducted on 150 HCV infected patients and 100 apparently healthy control subjects. All patients were treated with PEG-IFN/RBV. They were classified according to their response to treatment.Genotyping of IL-10, TNF-α, IFN-γ and TGF-β were performed on peripheral blood DNA using polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) and primer specific assays.ResultsOverall, 83/150 (55.3%) patients achieved sustained virological response (SVR), whereas 67 (44.7%) did not. Age and BMI were significantly lower in patients who achieved SVR (P < 0.05). IL-10 at site (â1082) GG genotype was associated with SVR where odds ratio was 1.98 with 95% confidence interval (1.34-3.65). None of the other genes showed a significant association with SVR.ConclusionAnalysis of IL-10 SNP at promoter site (â1082) could be used as a pretreatment predictor of response to combined PEG-IFN/RBV treatment.
Journal: Egyptian Journal of Medical Human Genetics - Volume 18, Issue 2, April 2017, Pages 111-119